Abacavir does not influence the rate of sustained virological response in HIV-HCV co-infected patients treated with pegylated interferon and weight adjusted ribavirin

摘要

IntroductionCombination of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) is the standard-of-care for hepatitis C virus (HCV) treatment in HIV coinfected individuals. In 2007, abacavir (ABC)-based antiretroviral therapy was for the first time reported to be associated with early virological failure during HCV treatment. The aim of our study was to evaluate the impact of ABC on the response rate to HCV-therapy.